News
ROIVW
2.750
-3.85%
-0.110
UPDATE 1-Moderna shares fall after judge sides with Arbutus in patent fight
Moderna shares fall after judge sides with Arbutus in patent fight. Shares of Moderna MRNA.O fell 4% in afternoon trading. A U.S. Judge interpreted parts of the patents in ways that strengthened Ar butus' case. The lawsuit is related to Moderna's blockbuster COVID-19 vaccines.
Reuters · 04/03 18:48
BUZZ-Moderna slides after judge sides with Arbutus in patent fight
U.S. Judge sides with Arbutus in patent infringement lawsuit related to MRNA's blockbuster vaccines. Shares of Moderna slide 3.5% to $100 after the news. MRNA is a joint venture of MRNA and Roivant Sciences. Ar butus shares up 12.1% in after-hours trading.
Reuters · 04/03 18:15
ROIVANT SCIENCES LTD. <ROIV.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $18 FROM $17
Reuters · 04/03 10:06
BUZZ-U.S. STOCKS ON THE MOVE-Paychex, ChampionX, EV stocks
Wall Street's main indexes drop on Tuesday. Dow Jones Industrial Average was down 1.24% at 39,076.51. Top three S&P 500 percentage gainers: GE, Phillips 66 and Freeport-McMoran. Biggest decliners were Tesla and UnitedHealth Group.
Reuters · 04/02 17:56
BUZZ-U.S. STOCKS ON THE MOVE-VirTra, GE Vernova, Blackstone
U.S. Stock indexes fell on Tuesday. The Dow Jones Industrial Average was down 1.24% and the S&P 500 and Nasdaq Composite were also down. Investors grew concerned about the possibility of fewer interest rate cuts than expected from the Federal Reserve. GE Vernova was one of the top gainers on the NYSE.
Reuters · 04/02 16:27
BUZZ-U.S. STOCKS ON THE MOVE-PVH, Verve Therapeutics, Canoo
Wall Street set to open lower on Tuesday. Dow e-minis down 0.81% ahead of comments from Federal Reserve policymakers. Top three NYSE percentage gainers: Ihuman, Verve Therapeutics, Canoo. PVH Corp down 21.9% premarket; Humana down 11.2%.
Reuters · 04/02 13:26
BUZZ-Roivant jumps after anti-inflammatory drug succeeds in mid-stage study
Roivant Sciences shares up 7.4% at $11.20 in premarket trading. Company says its experimental drug to treat -infectious uveitis succeeds in mid-stage study. Anti-inflammatory drug helped reduce symptoms of the inflammatory eye disease in the study.
Reuters · 04/02 12:08
UPDATE 2-Roivant's anti-inflammatory drug shows promise in mid-stage study
Roivant Sciences' shares up 8% after drug shows promise in mid-stage study. The drug, brepocitinib, helped reduce symptoms of the inflammatory eye disease uveitis. Analyst say drug could benefit patients more than Abbvie's Humira. Roivant expects drug to be multi-billion dollar opportunity.
Reuters · 04/02 11:21
BRIEF-Sumitomo Pharma Co: To Book About 55 Billion Yen Gain On Sale Of Roivant Sciences Shares In Parent-Only Q1 FY2025 Earnings
Sumitomo Pharma Co: To Book About 55 Billion Yen Gain On Sale Of Roivant Sciences Shares In Parent-Only Q1 FY2025 Earnings. 4506.T: To book about 55 billion yen gain on sale of shares in parent-only quarter.
Reuters · 04/02 11:03
ROIVANT ANNOUNCES POSITIVE NEPTUNE STUDY RESULTS FOR BREPOCITINIB IN NIU, AS WELL AS BOARD AUTHORIZATION FOR UP TO $1.5 BILLION SHARE REPURCHASE PROGRAM, INCLUDING REPURCHASE OF ENTIRE SUMITOMO PHARMA STAKE FOR $648 MILLION
Reuters · 04/02 11:00
BUZZ-U.S. STOCKS ON THE MOVE-Netflix, Reddit, Stoke Therapeutics
The Dow Jones Industrial Average was up 0.72% on Wednesday. Merck & Co hit record high as FDA approves therapy for rare lung condition. Reddit Inc up 46% in fifth day of trading. Netflix, Reddit, Stoke Therapeutics are among the day's top stocks.
Reuters · 03/27 17:45
BUZZ-U.S. STOCKS ON THE MOVE-Spirit Airlines, Cintas, Reddit
Dow Jones Industrial Average up 0.55% in thin trading ahead of long holiday weekend. Spirit Airlines, Cintas, Reddit among top gainers on Wall Street. U.S. Stock indexes rise ahead of crucial economic data and commentary from the Federal Reserve's policymakers.
Reuters · 03/27 15:48
BUZZ-Roivant rallies as co poised to join S&P MidCap index
Roivant Sciences' ROIV.O shares up 6.4% at $10.73, a 2-week high, in early Weds trade. Biotech firm poised to join S&P MidCap 400 index. Shares on course for biggest daily pct gain in six months.
Reuters · 03/27 14:10
Weekly Report: what happened at ROIVW last week (0226-0301)?
Weekly Report · 03/04 10:28
Weekly Report: what happened at ROIVW last week (0219-0223)?
Weekly Report · 02/26 10:35
Weekly Report: what happened at ROIVW last week (0212-0216)?
Weekly Report · 02/19 10:37
BUZZ-Bicycle Therapeutics jumps as Baker Bros boosts stake
Bicycle Therapeutics plc up 9.8% premarket to $19.12. Shares of UK-based oncology-focused biotech firm up about 1-mth. Baker Bros Advisors increases its stake in the company to 12.8%. Shares of Bicycle have lost 37% over the past year.
Reuters · 02/13 14:07
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
Barchart · 02/13 06:00
Weekly Report: what happened at ROIVW last week (0205-0209)?
Weekly Report · 02/12 10:30
Weekly Report: what happened at ROIVW last week (0129-0202)?
Weekly Report · 02/05 10:35
More
Webull provides a variety of real-time ROIVW stock news. You can receive the latest news about Roivant Sciences through multiple platforms. This information may help you make smarter investment decisions.
About ROIVW
Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company that seeks to improve the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline is focused on inflammation and immunology and includes VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; batoclimab and IMVT-1402, fully human monoclonal antibodies targeting the neonatal Fc receptor (FcRn) in development across several IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody in development for ulcerative colitis and Crohn’s disease, in addition to various other therapies in various stages of clinical development. The Company advances its pipeline by creating nimble subsidiaries or Vants to develop and commercialize its medicines and technologies. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.